Cancer and Metastasis Reviews

, Volume 31, Issue 3–4, pp 615–620 | Cite as

Raf kinase inhibitor protein (RKIP) in cancer



Raf kinase inhibitory protein (RKIP) was initially identified as phosphatidylethanolamine binding protein in bovine brain. It was later identified as a protein that inhibits Raf kinase activation of MEK. Further exploration has revealed that RKIP modulates several other signaling pathways including NF–κB and G-protein signaling. A gene array screen revealed that RKIP expression was low in a metastatic compared with non-metastatic prostate cancer cell line. Further experiments revealed that RKIP fits the criteria for a metastasis suppressor gene. RKIP expression has been shown to be downregulated in metastatic tissues, compared with non-metastatic tissue in multiple cancers, suggesting that loss of RKIP metastasis suppressor activity is a broad mechanism leading to metastasis. Additionally, loss of RKIP has been shown to impact therapy through conferring radioresistance and chemoresistance. Taken together, these data indicate understanding RKIP’s contributions to cancer may lead to important therapeutic strategies to prevent metastasis and promote therapeutic efficacy.


Metastasis Chemoresistance Radioresistance Prostate cancer RKIP 


  1. 1.
    Bernier, I., & Jolles, P. (1984). Purification and characterization of a basic 23 kDa cytosolic protein from bovine brain. Biochimica et Biophysica Acta, 790(2), 174–181.PubMedCrossRefGoogle Scholar
  2. 2.
    Perry, A. C., Hall, L., Bell, A. E., & Jones, R. (1994). Sequence analysis of a mammalian phospholipid-binding protein from testis and epididymis and its distribution between spermatozoa and extracellular secretions. Biochemical Journal, 301(Pt 1), 235–242.PubMedGoogle Scholar
  3. 3.
    Grandy, D. K., Hanneman, E., Bunzow, J., Shih, M., Machida, C. A., Bidlack, J. M., et al. (1990). Purification, cloning, and tissue distribution of a 23-kDa rat protein isolated by morphine affinity chromatography. Molecular Endocrinology, 4(9), 1370–1376.PubMedCrossRefGoogle Scholar
  4. 4.
    Bollengier, F., & Mahler, A. (1988). Localization of the novel neuropolypeptide h3 in subsets of tissues from different species. Journal of Neurochemistry, 50(4), 1210–1214.PubMedCrossRefGoogle Scholar
  5. 5.
    Hori, N., Chae, K. S., Murakawa, K., Matoba, R., Fukushima, A., Okubo, K., et al. (1994). A human cDNA sequence homologue of bovine phosphatidylethanolamine-binding protein. Gene, 140(2), 293–294.PubMedCrossRefGoogle Scholar
  6. 6.
    Seddiqi, N., Bollengier, F., Alliel, P. M., Perin, J. P., Bonnet, F., Bucquoy, S., et al. (1994). Amino acid sequence of the Homo sapiens brain 21–23-kDa protein (neuropolypeptide h3), comparison with its counterparts from Rattus norvegicus and Bos taurus species, and expression of its mRNA in different tissues. Journal of Molecular Evolution, 39(6), 655–660.PubMedCrossRefGoogle Scholar
  7. 7.
    Banfield, M. J., Barker, J. J., Perry, A. C., & Brady, R. L. (1998). Function from structure? The crystal structure of human phosphatidylethanolamine-binding protein suggests a role in membrane signal transduction. Structure, 6(10), 1245–1254.PubMedCrossRefGoogle Scholar
  8. 8.
    Fu, Z., Smith, P. C., Zhang, L., Rubin, M. A., Dunn, R. L., Yao, Z., et al. (2003). Effects of raf kinase inhibitor protein expression on suppression of prostate cancer metastasis. Journal of the National Cancer Institute, 95(12), 878–889.PubMedCrossRefGoogle Scholar
  9. 9.
    Simister, P. C., Banfield, M. J., & Brady, R. L. (2002). The crystal structure of PEBP-2, a homologue of the PEBP/RKIP family. Acta Crystallographica Section D: Biological Crystallography, 58(Pt 6 Pt 2), 1077–1080.CrossRefGoogle Scholar
  10. 10.
    Park, S., Yeung, M. L., Beach, S., Shields, J. M., & Yeung, K. C. (2005). RKIP downregulates B-Raf kinase activity in melanoma cancer cells. Oncogene, 24, 3535–3540.PubMedCrossRefGoogle Scholar
  11. 11.
    Yeung, K., Seitz, T., Li, S., Janosch, P., McFerran, B., Kaiser, C., et al. (1999). Suppression of Raf-1 kinase activity and MAP kinase signalling by RKIP. Nature, 401(6749), 173–177. doi: 10.1038/43686.PubMedCrossRefGoogle Scholar
  12. 12.
    Yeung, K. C., Rose, D. W., Dhillon, A. S., Yaros, D., Gustafsson, M., Chatterjee, D., et al. (2001). Raf kinase inhibitor protein interacts with NF-kappaB-inducing kinase and TAK1 and inhibits NF-kappaB activation. Molecular and Cellular Biology, 21(21), 7207–7217.PubMedCrossRefGoogle Scholar
  13. 13.
    Park, S., Rath, O., Beach, S., Xiang, X., Kelly, S. M., Luo, Z., et al. (2006). Regulation of RKIP binding to the N-region of the Raf-1 kinase. FEBS Letters, 580(27), 6405–6412.PubMedCrossRefGoogle Scholar
  14. 14.
    Rath, O., Park, S., Tang, H. H., Banfield, M. J., Brady, R. L., Lee, Y. C., et al. (2008). The RKIP (Raf-1 kinase inhibitor protein) conserved pocket binds to the phosphorylated N-region of Raf-1 and inhibits the Raf-1-mediated activated phosphorylation of MEK. Cellular Signalling, 20(5), 935–941.PubMedCrossRefGoogle Scholar
  15. 15.
    Yeung, K., Janosch, P., McFerran, B., Rose, D. W., Mischak, H., Sedivy, J. M., et al. (2000). Mechanism of suppression of the Raf/MEK/extracellular signal-regulated kinase pathway by the Raf kinase inhibitor protein. Molecular and Cellular Biology, 20(9), 3079–3085.PubMedCrossRefGoogle Scholar
  16. 16.
    Al-Mulla, F., Bitar, M. S., Al-Maghrebi, M., Behbehani, A. I., Al-Ali, W., Rath, O., et al. (2011). Raf kinase inhibitor protein RKIP enhances signaling by glycogen synthase kinase-3beta. Cancer Research, 71(4), 1334–1343.PubMedCrossRefGoogle Scholar
  17. 17.
    Al-Mulla, F., Bitar, M. S., Feng, J., Park, S., & Yeung, K. C. (2012). A new model for Raf kinase inhibitory protein induced chemotherapeutic resistance. PLoS One, 7(1), e29532. doi: 10.1371/journal.pone.0029532.PubMedCrossRefGoogle Scholar
  18. 18.
    Chatterjee, D., Sabo, E., Tavares, R., & Resnick, M. B. (2008). Inverse association between Raf kinase inhibitory protein and signal transducers and activators of transcription 3 expression in gastric adenocarcinoma patients: Implications for clinical outcome. Clinical Cancer Research, 14(10), 2994–3001.PubMedCrossRefGoogle Scholar
  19. 19.
    Lorenz, K., Lohse, M. J., & Quitterer, U. (2003). Protein kinase C switches the Raf kinase inhibitor from Raf-1 to GRK-2. Nature, 426(6966), 574–579.PubMedCrossRefGoogle Scholar
  20. 20.
    Tang, H., Park, S., Sun, S. C., Trumbly, R., Ren, G., Tsung, E., et al. (2010). RKIP inhibits NF-kappaB in cancer cells by regulating upstream signaling components of the IkappaB kinase complex. FEBS Letters, 584(4), 662–668.PubMedCrossRefGoogle Scholar
  21. 21.
    Corbit, K. C., Trakul, N., Eves, E. M., Diaz, B., Marshall, M., & Rosner, M. R. (2003). Activation of Raf-1 signaling by protein kinase C through a mechanism involving Raf kinase inhibitory protein. Journal of Biological Chemistry, 278(15), 13061–13068.PubMedCrossRefGoogle Scholar
  22. 22.
    Germain, D., & Frank, D. A. (2007). Targeting the cytoplasmic and nuclear functions of signal transducers and activators of transcription 3 for cancer therapy. Clinical Cancer Research, 13(19), 5665–5669.PubMedCrossRefGoogle Scholar
  23. 23.
    Al-Mulla, F., Hagan, S., Behbehani, A. I., Bitar, M. S., George, S. S., Going, J. J., et al. (2006). Raf kinase inhibitor protein expression in a survival analysis of colorectal cancer patients. Journal of Clinical Oncology, 24(36), 5672–5679.PubMedCrossRefGoogle Scholar
  24. 24.
    Chatterjee, D., Bai, Y., Wang, Z., Beach, S., Mott, S., Roy, R., et al. (2004). RKIP sensitizes prostate and breast cancer cells to drug-induced apoptosis. Journal of Biological Chemistry, 279(17), 17515–17523.PubMedCrossRefGoogle Scholar
  25. 25.
    Hagan, S., Al-Mulla, F., Mallon, E., Oien, K. A., Ferrier, R., Gusterson, B., et al. (2005). Reduction of Raf-1 kinase inhibitor protein expression correlates with breast cancer metastases. Clinical Cancer Research 11:7392-7397. Google Scholar
  26. 26.
    Lee, H. C., Tian, B., Sedivy, J. M., Wands, J. R., & Kim, M. (2006). Loss of Raf kinase inhibitor protein promotes cell proliferation and migration of human hepatoma cells. Gastroenterology, 131(4), 1208–1217.PubMedCrossRefGoogle Scholar
  27. 27.
    Schuierer, M. M., Bataille, F., Hagan, S., Kolch, W., & Bosserhoff, A. K. (2004). Reduction in Raf kinase inhibitor protein expression is associated with increased Ras-extracellular signal-regulated kinase signaling in melanoma cell lines. Cancer Research, 64(15), 5186–5192.PubMedCrossRefGoogle Scholar
  28. 28.
    Schuierer, M. M., Bataille, F., Weiss, T. S., Hellerbrand, C., & Bosserhoff, A. K. (2006). Raf kinase inhibitor protein is downregulated in hepatocellular carcinoma. Oncology Reports, 16(3), 451–456.PubMedGoogle Scholar
  29. 29.
    Zhang, L., Fu, Z., Binkley, C., Giordano, T., Burant, C. F., Logsdon, C. D., et al. (2004). Raf kinase inhibitory protein inhibits beta-cell proliferation. Surgery, 136(3), 708–715.PubMedCrossRefGoogle Scholar
  30. 30.
    Lopez, M., Maroc, N., Kerangueven, F., Bardin, F., Courcoul, M., Lavezzi, C., et al. (1991). Coexpression of the genes for interleukin 6 and its receptor without apparent involvement in the proliferation of acute myeloid leukemia cells. Experimental Hematology, 19, 797–803.PubMedGoogle Scholar
  31. 31.
    Martinho, O., Faloppa, C. C., Neto, C. S., Longatto-Filho, A., Baiocchi, G., da Cunha, I. W., et al. (2012). Loss of RKIP expression during the carcinogenic evolution of endometrial cancer. Journal of Clinical Pathology, 65(2), 122–128. doi: 10.1136/jclinpath-2011-200358.PubMedCrossRefGoogle Scholar
  32. 32.
    Jia, B., Liu, H., Kong, Q., & Li, B. (2012). RKIP expression associated with gastric cancer cell invasion and metastasis. Tumour Biology: The Journal of the International Society for Oncodevelopmental Biology and Medicine. doi: 10.1007/s13277-012-0317-3.
  33. 33.
    Zaravinos, A., Chatziioannou, M., Lambrou, G. I., Boulalas, I., Delakas, D., & Spandidos, D. A. (2011). Implication of RAF and RKIP genes in urinary bladder cancer. Pathology Oncology Research: POR, 17(2), 181–190. doi: 10.1007/s12253-010-9295-1.PubMedCrossRefGoogle Scholar
  34. 34.
    Fu, Z., Kitagawa, Y., Shen, R., Shah, R., Mehra, R., Rhodes, D., et al. (2006). Metastasis suppressor gene Raf kinase inhibitor protein (RKIP) is a novel prognostic marker in prostate cancer. Prostate, 66(3), 248–256. doi: 10.1002/pros.20319.PubMedCrossRefGoogle Scholar
  35. 35.
    Beshir, A. B., Ren, G., Magpusao, A. N., Barone, L. M., Yeung, K. C., & Fenteany, G. (2010). Raf kinase inhibitor protein suppresses nuclear factor-kappaB-dependent cancer cell invasion through negative regulation of matrix metalloproteinase expression. Cancer Letters, 299(2), 137–149.PubMedCrossRefGoogle Scholar
  36. 36.
    Dangi-Garimella, S., Yun, J., Eves, E. M., Newman, M., Erkeland, S. J., Hammond, S. M., et al. (2009). Raf kinase inhibitory protein suppresses a metastasis signalling cascade involving LIN28 and let-7. EMBO Journal, 28(4), 347–358.PubMedCrossRefGoogle Scholar
  37. 37.
    Martinho, O., Granja, S., Jaraquemada, T., Caeiro, C., Miranda-Goncalves, V., Honavar, M., et al. (2012). Downregulation of RKIP is associated with poor outcome and malignant progression in gliomas. PLoS One, 7(1), e30769. doi: 10.1371/journal.pone.0030769.PubMedCrossRefGoogle Scholar
  38. 38.
    Yun, J., Frankenberger, C. A., Kuo, W. L., Boelens, M. C., Eves, E. M., Cheng, N., et al. (2011). Signalling pathway for RKIP and Let-7 regulates and predicts metastatic breast cancer. EMBO Journal, 30(21), 4500–4514.PubMedCrossRefGoogle Scholar
  39. 39.
    Sears, R., Leone, G., DeGregori, J., & Nevins, J. R. (1999). Ras enhances Myc protein stability. Molecular Cell, 3(2), 169–179.PubMedCrossRefGoogle Scholar
  40. 40.
    Xinzhou, H., Ning, Y., Ou, W., Xiaodan, L., Fumin, Y., Huitu, L., et al. (2011). RKIp inhibits the migration and invasion of human prostate cancer PC-3 M cells through regulation of extracellular matrix [Research Support, non-U.S.-Gov’t]. Molekuliarnaia Biologiia, 45(6), 1004–1011.PubMedGoogle Scholar
  41. 41.
    Baritaki, S., & Bonavida, B. (2010). Viral infection and cancer: The NF-kappaB/Snail/RKIP loop regulates target cell sensitivity to apoptosis by cytotoxic lymphocytes. Critical Reviews in Immunology, 30(1), 31–46.PubMedCrossRefGoogle Scholar
  42. 42.
    Baritaki, S., Katsman, A., Chatterjee, D., Yeung, K. C., Spandidos, D. A., & Bonavida, B. (2007). Regulation of tumor cell sensitivity to TRAIL-induced apoptosis by the metastatic suppressor Raf kinase inhibitor protein via Yin Yang 1 inhibition and death receptor 5 up-regulation. Journal of Immunology, 179, 5441–5453.Google Scholar
  43. 43.
    Baritaki, S., Yeung, K., Palladino, M., Berenson, J., & Bonavida, B. (2009). Pivotal roles of snail inhibition and RKIP induction by the proteasome inhibitor NPI-0052 in tumor cell chemoimmunosensitization. Cancer Research, 69(21), 8376–8385.PubMedCrossRefGoogle Scholar
  44. 44.
    Woods Ignatoski, K. M., Grewal, N. K., Markwart, S. M., Vellaichamy, A., Chinnaiyan, A. M., Yeung, K., et al. (2008). Loss of Raf kinase inhibitory protein induces radioresistance in prostate cancer. International Journal of Radiation Oncology, Biology, and Physics, 72(1), 153–160.CrossRefGoogle Scholar
  45. 45.
    Kobayashi, A., Ohta, T., & Yamamoto, M. (2004). Unique function of the Nrf2-Keap1 pathway in the inducible expression of antioxidant and detoxifying enzymes. Methods in Enzymology, 378, 273–286. doi: 10.1016/S0076-6879(04)78021-0.PubMedCrossRefGoogle Scholar
  46. 46.
    Lee, J. M., Calkins, M. J., Chan, K., Kan, Y. W., & Johnson, J. A. (2003). Identification of the NF-E2-related factor-2-dependent genes conferring protection against oxidative stress in primary cortical astrocytes using oligonucleotide microarray analysis. Journal of Biological Chemistry, 278(14), 12029–12038. doi: 10.1074/jbc.M211558200.PubMedCrossRefGoogle Scholar
  47. 47.
    Venugopal, R., & Jaiswal, A. K. (1996). Nrf1 and Nrf2 positively and c-Fos and Fra1 negatively regulate the human antioxidant response element-mediated expression of NAD(P)H:quinone oxidoreductase1 gene. Proceedings of the National Academy of Sciences of the United States of America, 93(25), 14960–14965.PubMedCrossRefGoogle Scholar
  48. 48.
    Thimmulappa, R. K., Mai, K. H., Srisuma, S., Kensler, T. W., Yamamoto, M., & Biswal, S. (2002). Identification of Nrf2-regulated genes induced by the chemopreventive agent sulforaphane by oligonucleotide microarray. Cancer Research, 62(18), 5196–5203.PubMedGoogle Scholar
  49. 49.
    Hu, C. J., Zhou, L., Zhang, J., Huang, C., & Zhang, G. M. (2011). Immunohistochemical detection of Raf kinase inhibitor protein in normal cervical tissue and cervical cancer tissue. The Journal of International Medical Research, 39(1), 229–237.PubMedGoogle Scholar
  50. 50.
    Huerta-Yepez, S., Yoon, N. K., Hernandez-Cueto, A., Mah, V., Rivera-Pazos, C. M., Chatterjee, D., et al. (2011). Expression of phosphorylated raf kinase inhibitor protein (pRKIP) is a predictor of lung cancer survival. BMC Cancer, 11, 259. doi: 10.1186/1471-2407-11-259.PubMedCrossRefGoogle Scholar
  51. 51.
    Ruan, L., Wang, G. L., Yi, H., Chen, Y., Tang, C. E., Zhang, P. F., et al. (2010). Raf kinase inhibitor protein correlates with sensitivity of nasopharyngeal carcinoma to radiotherapy. [Research Support, non-U.S.-Gov’t]. Journal of Cellular Biochemistry, 110(4), 975–981. doi: 10.1002/jcb.22611.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.Department of UrologyUniversity of MichiganAnn ArborUSA
  2. 2.Department of Biochemistry and Cancer BiologyUniversity of ToledoToledoUSA

Personalised recommendations